Search
Feed aggregator
Beyond GLP-1s: The Next Obesity Treatments
Beyond GLP-1s: The Next Obesity Treatments 7/8/2024
Drug Developers Tap the Immune System to Supercharge ADCs
Drug Developers Tap the Immune System to Supercharge ADCs 7/8/2024
Patient Assistance Programs: A Source of Real-World Data?
Patient Assistance Programs: A Source of Real-World Data? 7/8/2024
Regeneron’s Gene Therapy Shows ‘Dramatic’ Hearing Improvement in Deaf Kids
Regeneron’s Gene Therapy Shows ‘Dramatic’ Hearing Improvement in Deaf Kids 5/8/2024
ASGCT2024: FDA’s Marks on Accelerated Approval, Gene Therapy Costs and More
ASGCT2024: FDA’s Marks on Accelerated Approval, Gene Therapy Costs and More 5/8/2024
Sarepta Seeks Label Expansion, Bigger Market for DMD Gene Therapy
Sarepta Seeks Label Expansion, Bigger Market for DMD Gene Therapy 5/8/2024
AstraZeneca Withdraws COVID-19 Vaccine Worldwide as Demand Craters
AstraZeneca Withdraws COVID-19 Vaccine Worldwide as Demand Craters 5/8/2024
Pfizer Halts Dosing in Late-Stage DMD Study Following Death of Young Patient
Pfizer Halts Dosing in Late-Stage DMD Study Following Death of Young Patient 5/8/2024
Lykos Therapeutics’ MDMA Therapy for PTSD to Face FDA Adcomm
Lykos Therapeutics’ MDMA Therapy for PTSD to Face FDA Adcomm 5/8/2024
ASGCT, Adcomm for Lilly’s Donanemab, Vertex Vs. Bluebird
ASGCT, Adcomm for Lilly’s Donanemab, Vertex Vs. Bluebird 5/8/2024
Generative AI Finds Its Footing in Drug Development
Generative AI Finds Its Footing in Drug Development 5/8/2024
BMS, J&J Losses Not the End of IRA Legal Battle
BMS, J&J Losses Not the End of IRA Legal Battle 5/8/2024
Merck Snaps Up Small Startup in $208M Deal, Seeks to Improve Safety of ADCs
Merck Snaps Up Small Startup in $208M Deal, Seeks to Improve Safety of ADCs 4/8/2024
BMS Sees Early ROI for $14B Karuna Buy with Phase III Schizophrenia Win
BMS Sees Early ROI for $14B Karuna Buy with Phase III Schizophrenia Win 4/8/2024
ACC24 Roundup: Novo, Ionis Tout Cardio Victories and Boehringer, Lilly Disappoint
ACC24 Roundup: Novo, Ionis Tout Cardio Victories and Boehringer, Lilly Disappoint 4/8/2024
5 Successful Phase III Oncology Trials in Q1
5 Successful Phase III Oncology Trials in Q1 4/8/2024
The Next Wave of ADCs Could Treat Evasive Solid Tumors
The Next Wave of ADCs Could Treat Evasive Solid Tumors 4/8/2024
AstraZeneca, Daiichi Sankyo Win First Tumor-Agnostic HER2 FDA Approval for Enhertu
AstraZeneca, Daiichi Sankyo Win First Tumor-Agnostic HER2 FDA Approval for Enhertu 4/8/2024
FDA Again Rejects Supernus Drug-Device Combo for Parkinson’s Disease
FDA Again Rejects Supernus Drug-Device Combo for Parkinson’s Disease 4/8/2024
Opinion: The Next Generation of ADCs Will Improve Cancer Treatment
Opinion: The Next Generation of ADCs Will Improve Cancer Treatment 4/8/2024
World Pharma News
- Novel drug application shows improved survival for patients with relapsed and refractory acute myeloid leukemia
- Study shows ancient viruses fuel modern-day cancers
- Darolutamide meets primary endpoint in Phase III ARANOTE trial
- Pfizer advances development of once-daily formulation of oral GLP-1 receptor agonist danuglipron
- New AI approach optimizes antibody drugs